The Acquirer's Playbook: How a Pharma VP Actually Chooses What to Buy

Article 2 of 2 in The M&A Playbook: Both Sides of the Table Series

A practical, step-by-step decision framework built from five years of deal data — for the person on the buying side of the table

Prepared by Richstorm.co

KEY TAKEAWAYS

• Map your own patent cliff exposure before evaluating any target — the acquisition thesis starts with your own numbers, not the target's.

• Internal development's $2.6 billion, 10-15 year cost is the real benchmark every build-partner-buy decision should be measured against.

• Audit modality gaps separately from disease-area gaps — Novartis was already an oncology leader but still needed a dedicated ADC acquisition to close a platform gap.

• A target with a credible standalone financing path can extend negotiations for months and meaningfully raise the final price, as Novartis found with Avidity.

• Antitrust cost is a real line item: Pfizer and Amgen both paid concessions worth hundreds of millions to close their largest recent deals.

If you are the person inside a large pharmaceutical company responsible for deciding what to acquire, the question is never “what's interesting?” It's “what solves a problem we already know we have, on a timeline we don't control?” That problem, for almost every large acquirer right now, is the same one: an estimated $300 billion in annual prescription drug revenue is scheduled to lose patent protection between 2025 and 2030, with five of the top ten pharmaceutical companies facing exposure above 50% of current revenue. Any acquisition thesis starts with mapping that constraint — which of your own products lose exclusivity, and when — before a single target company enters the conversation. The six steps below walk through that process in order, from the first internal decision to the final regulatory sign-off.

Step 1: Decide Whether to Build, Partner, or Buy

Before evaluating any specific target, the decision is which mechanism to use at all. Internal drug development is the baseline every other option gets measured against — and it is expensive and slow enough that it rarely wins by default:

Step 2: Run the Screening Checklist

Once you've decided speed or de-risked science matters more than building in-house, public reporting and industry analysis converge on a consistent set of screening criteria for any specific target. Treat this as the rubric, not a vibe check:

Step 3: Choose Your Risk Posture

There are two structurally different ways to de-risk an acquisition, and the choice matters more than most target-selection frameworks acknowledge:

Neither approach is universally better. Partner-first costs you years and gives a rival the chance to buy the same target out from under you; cold acquisition is faster but means paying a full, undiscounted price for unresolved scientific risk. The right posture depends on how much time your patent cliff gives you and how much competitive pressure exists for the specific mechanism you need.

Check Your Modality Gaps, Not Just Your Disease-Area Gaps

The screening checklist in Step 2 and the risk posture in Step 3 both assume you already know what you're looking for — but “what we're missing” is a two-dimensional question, not a one-dimensional one. Therapeutic area is one axis; modality (the underlying technology — antibody-drug conjugates, radiopharmaceuticals, RNA-based therapies, cell therapy) is a separate axis, and a company can be fully committed to a disease area while still lacking a specific modality within it. When Novartis paid over $1 billion for Myricx Bio, an ADC company, in 2026, its head of biomedical research, Fiona Marshall, said directly the deal “reflects our strategy to scale innovative platforms, as we have with radioligand therapies.” Novartis was already one of the largest oncology players in the industry — the acquisition wasn't about entering a new disease area, it was about closing a specific modality gap inside an area it already dominated.

Modality waves also move somewhat independently of therapeutic area, and are worth auditing in your own portfolio the same way you'd audit disease-area coverage. More than $13 billion has been committed to radioligand deals industry-wide since 2023 — BMS/RayzeBio, AstraZeneca/Fusion, Lilly/POINT, and Novartis/Mariana among them — largely because Novartis proved the modality itself works commercially (its radioligand drug Pluvicto reached roughly $2 billion in 2025 sales, up 42% year over year). Once one company proves a modality works, competitors move toward the same underlying technology regardless of which specific diseases they each target — which means a modality gap in your own portfolio can become urgent almost overnight.

Step 4: Know Where to Actually Look

Three sourcing channels matter beyond the obvious banker-run auction process:

Step 5: Don't Underestimate the Target's Leverage

It is tempting to assume a smaller company has no negotiating power against a much larger acquirer. The Novartis–Avidity Biosciences deal is a useful corrective. Novartis's CEO opened with a $7.4 billion offer and a four-week close; Avidity's CEO rejected it, and at one point walked away entirely — cutting off data room access and moving forward with an independent $690 million capital raise instead. Only after Avidity demonst

rated it had a credible path to remaining independent did Novartis return with a substantially improved offer, ultimately closing at roughly $12 billion. A target with a credible standalone financing path is not a target you can lowball.

The premiums this dynamic produces are worth knowing before you make a first offer: published data point to median acquisition premiums of 50–65% over the unaffected stock price, with late-stage but not-yet-approved assets commanding roughly 30–60%, approved drugs commanding 50–100%+, and competitive bidding among multiple acquirers pushing premiums to 50–150%+ in some cases.

Step 6: Price In the Regulatory Cost

Antitrust exposure is a real, sometimes multi-hundred-million-dollar cost that belongs in the acquisition thesis, not treated as an afterthought. Pfizer's $43 billion Seagen deal cleared the FTC only after Pfizer agreed to donate all future U.S. royalty rights on an unrelated cancer drug (Bavencio) to a research nonprofit. Amgen's $27.8 billion Horizon deal was met with an outright FTC lawsuit — the Commission's first challenge to an unconsummated pharma merger in over fourteen years — and only closed after a consent order barring Amgen from bundling Horizon's rare disease drugs with its own portfolio.